SpectronRx Email Format

Pharmaceutical ManufacturingIndiana, United States51-200 Employees

SpectronRx is a radiopharmaceutical contract development and manufacturing organization (CDMO/CMO) in the pharmaceutical manufacturing sector. The company holds FDA and EMA inspections and is licensed to handle multiple therapeutic and diagnostic isotopes, including Pb-212, Lu-177, Ac-225, and I-131, for clinical applications. Its quality program has been inspected by the FDA with approved drugs such as FDG, NaF, and Ammonia. In addition to manufacturing, SpectronRx provides labeling and contract manufacturing services for isotopes including Lu-177, Ac-225, I-131, I-124, In-111, Zr-89, Cu-64, and F-18. The company operates across multiple U.S. locations, including Indianapolis, South Bend, and Danbury, Connecticut, and employs between 51 and 200 people. In 2026, OrbiMed invested in SpectronRx, and Plus Therapeutics announced a collaboration under a master services agreement to support late-stage clinical manufacturing of Rhenium-186 and REYOBIQ.

Sign up for free to view info

Company overview Employee directory